Literature DB >> 25453574

First report of severe parainfluenza virus 4B and rhinovirus C coinfection in a liver transplant recipient treated with immunoglobulin.

Siddharth Sridhar1, Hayes K H Luk1, Susanna K P Lau2, Patrick C Y Woo3.   

Abstract

We describe the first reported case of severe pneumonia due to coinfection by parainfluenza virus type 4B and rhinovirus C in a liver transplant recipient. The patient responded promptly to intravenous immunoglobulin and timely infection control measures prevented spreading of the infections. This report highlights respiratory viral coinfections as a possible cause of severe morbidity in transplant recipients and the importance of efficient molecular diagnostic technologies with major impact on clinical practice in a transplant center. It also describes a potential therapeutic strategy for such patients.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Coinfection; Immunoglobulin; Parainfluenza; Rhinovirus; Transplantation

Mesh:

Substances:

Year:  2014        PMID: 25453574     DOI: 10.1016/j.jcv.2014.09.019

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  3 in total

1.  Unexpectedly Higher Morbidity and Mortality of Hospitalized Elderly Patients Associated with Rhinovirus Compared with Influenza Virus Respiratory Tract Infection.

Authors:  Ivan F N Hung; Anna Jinxia Zhang; Kelvin K W To; Jasper F W Chan; Shawn H S Zhu; Ricky Zhang; Tuen-Ching Chan; Kwok-Hung Chan; Kwok-Yung Yuen
Journal:  Int J Mol Sci       Date:  2017-01-26       Impact factor: 5.923

2.  Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy.

Authors:  Stefanie Prohaska; Andrea Schirner; Albina Bashota; Andreas Körner; Gunnar Blumenstock; Helene A Haeberle
Journal:  J Intensive Care       Date:  2018-02-26

Review 3.  Parainfluenza Virus Infection.

Authors:  Angela R Branche; Ann R Falsey
Journal:  Semin Respir Crit Care Med       Date:  2016-08-03       Impact factor: 3.119

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.